Geron Competitors

Geron (NASDAQ:GERN) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Risk and Volatility

Geron has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Geron and Amgen, as reported by MarketBeat.com.

Geron currently has a consensus target price of $4.20, suggesting a potential upside of 196.82%. Amgen has a consensus target price of $261.1429, suggesting a potential upside of 1.07%. Given Geron's stronger consensus rating and higher probable upside, research analysts clearly believe Geron is more favorable than Amgen.

Institutional and Insider Ownership

55.5% of Geron shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 7.7% of Geron shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Geron and Amgen's top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Geron and Amgen's net margins, return on equity and return on assets.

Summary

Amgen beats Geron on 9 of the 14 factors compared between the two stocks.

Geron (NASDAQ:GERN) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Geron and Gilead Sciences, as provided by MarketBeat.

Geron presently has a consensus price target of $4.20, indicating a potential upside of 196.82%. Gilead Sciences has a consensus price target of $97.68, indicating a potential upside of 46.27%. Given Geron's stronger consensus rating and higher probable upside, equities analysts clearly believe Geron is more favorable than Gilead Sciences.

Earnings & Valuation

This table compares Geron and Gilead Sciences' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

55.5% of Geron shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 7.7% of Geron shares are held by company insiders. Comparatively, 0.1% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Geron and Gilead Sciences' net margins, return on equity and return on assets.

Risk and Volatility

Geron has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Summary

Gilead Sciences beats Geron on 9 of the 14 factors compared between the two stocks.

Geron (NASDAQ:GERN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Geron and Vertex Pharmaceuticals, as provided by MarketBeat.

Geron presently has a consensus price target of $4.20, indicating a potential upside of 196.82%. Vertex Pharmaceuticals has a consensus price target of $293.2083, indicating a potential upside of 33.81%. Given Geron's stronger consensus rating and higher probable upside, equities research analysts plainly believe Geron is more favorable than Vertex Pharmaceuticals.

Valuation & Earnings

This table compares Geron and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

55.5% of Geron shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 7.7% of Geron shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Geron and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Volatility and Risk

Geron has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Geron on 10 of the 15 factors compared between the two stocks.

Geron (NASDAQ:GERN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Risk & Volatility

Geron has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Valuation and Earnings

This table compares Geron and Regeneron Pharmaceuticals' gross revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

55.5% of Geron shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 7.7% of Geron shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Geron and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Geron currently has a consensus price target of $4.20, indicating a potential upside of 196.82%. Regeneron Pharmaceuticals has a consensus price target of $644.1739, indicating a potential upside of 27.79%. Given Geron's stronger consensus rating and higher probable upside, analysts plainly believe Geron is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Geron and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Geron on 11 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Geron (NASDAQ:GERN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Risk and Volatility

Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Geron has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 55.5% of Geron shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 7.7% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Biogen and Geron's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Biogen and Geron, as reported by MarketBeat.

Biogen currently has a consensus target price of $303.3103, indicating a potential upside of 12.70%. Geron has a consensus target price of $4.20, indicating a potential upside of 196.82%. Given Geron's stronger consensus rating and higher possible upside, analysts clearly believe Geron is more favorable than Biogen.

Valuation & Earnings

This table compares Biogen and Geron's revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Geron on 9 of the 14 factors compared between the two stocks.

Geron (NASDAQ:GERN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Risk & Volatility

Geron has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Institutional and Insider Ownership

55.5% of Geron shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 7.7% of Geron shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Geron and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for Geron and Alexion Pharmaceuticals, as reported by MarketBeat.

Geron presently has a consensus price target of $4.20, indicating a potential upside of 196.82%. Alexion Pharmaceuticals has a consensus price target of $153.4286, indicating a potential downside of 8.82%. Given Geron's stronger consensus rating and higher possible upside, equities analysts plainly believe Geron is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Geron and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats Geron on 9 of the 15 factors compared between the two stocks.